Impact of smoking on dendritic cell phenotypes in the airway lumen of patients with COPD

Stoll, Paul; Heinz, Ann-Sophie; Bratke, Kai; Bier, Andrea; Garbe, Katharina; Kuepper, Michael; Virchow, J Christian; Lommatzsch, Marek

doi:10.1186/1465-9921-15-48

Respiratory Research

Table 1 Subject characteristics

From: Impact of smoking on dendritic cell phenotypes in the airway lumen of patients with COPD

	Control group (C) n = 10	COPD total group (T) n = 24	COPD current smoker (S) n = 13	COPD former smoker (F) n = 11	C-T p	C-S p	C-F p	S-F p
Age (years)	51.0 [40…68]	55.0 [35…73]	52.0 [35…63]	62.0 [38…73]	0.491	0.879	0.132	0.055
Gender (m / f)	6 / 4	18 / 6	10 / 3	8 / 3	NA	NA	NA	NA
BMI (kg*m⁻²)	25.6 [23.2…36.9]	24.5 [18.7…39.0]	23.0 [18.7…37.4]	31.1 [23.5…39.0]	0.360	0.021	0.426	0.007
Pack years	0.0 [0…0]	34.0 [10…60]	40.0 [15…60]	32.0 [10…50]	<0.001	<0.001	<0.001	0.284
Medication LABA without ICS/LABA plus ICS/LAMA	0 / 0 / 0	3 / 10 / 10	0 / 5 / 4	3 / 5 / 6	NA	NA	NA	NA
FEV₁ (% pred.)	114.3 [93.9…126.6]	63.6 [41.5…80.0]	65.2 [41.5…80.0]	62.0 [51.5…71.4]	<0.001	<0.001	<0.001	0.392
IVC (% pred.)	107.1 [82.6…116.8]	86.7 [29.3…114.4]	83.6 [29.3…114.4]	88.8 [35.2…97.9]	0.008	0.115	0.002	0.608
FEV₁% FVC (%)	82.5 [77.2…98.3]	60.5 [34.4…71.5]	60.5 [34.4…71.5]	60.5 [47.4…66.8]	<0.001	<0.001	<0.001	0.955
MEF50 (% pred.)	98.0 [72.2…156.2]	24.5 [11.7…39.4]	24.7 [11.7…39.4]	22.6 [16.9…32.0]	<0.001	<0.001	<0.001	0.649
RV (% pred.)	91.0 [79.6…136.0]	136.1 [87.1…185.4]	129.7 [115.3…185.4]	136.2 [87.1…183.8]	<0.001	<0.001	0.001	0.569
TLC (% pred.)	100.5 [85.8…121.5]	102.7 [86.1…148.9]	101.0 [89.3…148.9]	106.0 [86.1…127.0]	0.669	0.738	0.705	0.955
Hemoglobin (mmol/l)	9.2 [7.3…10.3]	9.1 [7.1…11.3]	9.3 [7.1…11.3]	8.9 [8.0…9.7]	0.809	0.832	0.468	0.531
Hematocrit (%)	43.0 [38.0…49.0]	44.0 [38…52]	45.0 [38.0…52.0]	41.0 [39.0…48.0]	0.897	0.605	0.756	0.691
Platelets (*10⁹/l)	229 [180…320]	236 [155…374]	246 [155…374]	226 [165…331]	0.985	0.693	0.705	0.608
Leukocytes (*10⁹/l)	5.9 [3.8…8.2]	7.5 [3.9…12.3]	7.7 [3.9…10.2]	7.3 [4.0…12.3]	0.101	0.077	0.314	0.955
CRP (mg/l)	1.1 [1.0…9.5]	2.1 [1.0…15.1]	1.9 [1.0…10.6]	2.3 [1.0…15.1]	0.170	0.446	0.099	0.459

Shown are general characteristics of the subjects, results of pulmonary function tests and blood parameters. All patients treated with inhaled corticosteroids (ICS) were also treated with a long-acting beta-agonist (LABA) in a fixed combination (“LABA plus ICS”). Parameters are displayed as median values [minimum…maximum]. Abbreviations denote: c-reactive protein (CRP), Inspiratory vital capacity (IVC), Forced expiratory volume in the first one second (FEV1), ratio of the FEV1 to the forced vital capacity (FEV1/FVC), maximum expiratory flow at 50% of VC (MEF50), residual volume (RV), total lung capacity (TLC). The four columns on the right side of the table show comparisons between the groups: Control vs. total group of COPD patients (C-T), Control vs. COPD (current smoker) (C-S), Control vs. COPD (former smoker) (C-F) and COPD (current smoker) vs. COPD (former smoker) (S-F).

Back to article page

ISSN: 1465-993X

Contact us

General enquiries: journalsubmissions@springernature.com